

Medicine Generic Name	Indication	Reference	Age Range	Approval Mechanism	Initiation Form Status	Continuation Form Status	NWJCC Directorate	NWJCC Policy	Commissioned Providers
<b>Acornamidis</b>	Treatment of transthyretin amyloidosis with cardiomyopathy	<b>TA1121</b>	18-110 years	BlueTEQ	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
<b>Adalimumab (M4C)</b>	Treatment of severe active Crohn's disease in children aged 2-5 years old	<b>TA187</b>	2-5 years	BlueTEQ	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
<b>Adalimumab (M4C)</b>	Treatment of severe active Crohn's disease in children aged 6-17 years old	<b>TA187</b>	6-17 years	BlueTEQ	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
<b>Adalimumab (M4C)</b>	Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy in children aged 2-5 years old	<b>TA329</b>	2-5 years	BlueTEQ	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
<b>Adalimumab (M4C)</b>	Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy in children aged 6-17 years old	<b>TA329</b>	6-17 years	BlueTEQ	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
<b>Agalsidase alfa</b>	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	<b>AWMSG 1107</b>	18-110 years	BlueTEQ	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Agalsidase beta</b>	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	<b>AWMSG 12</b>	18-110 years	BlueTEQ	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Alglucosidase alfa</b>	Long term enzyme replacement therapy in patients with a confirmed diagnosis of Pompe disease (α-D-glucosidase deficiency)	<b>AWMSG 0224</b>	0-110 years	BlueTEQ	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Anakinra</b>	Treatment for systemic juvenile idiopathic arthritis in people 8 months or older	<b>TA685</b>	8 months-17 years	BlueTEQ	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Great Ormond Street Hospital for Children NHS Foundation Trust Guy's and St. Thomas' Hospital NHS Foundation Trust Royal Free London NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust
<b>Anhydrous sodium thiosulfate</b>	Prevention of hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours	<b>TA1034</b>	1 month-17 years	BlueTEQ	Live	Not Applicable	Women & Children	PP5315	Alder Hey Children's NHS Foundation Trust Birmingham Women and Children's NHS Foundation Trust Cardiff and Vale University Health Board Velindre NHS Trust
<b>Asfotase alfa</b>	Treatment of paediatric-onset hypophosphatasia in babies, children, young people and adults	<b>HST23</b>	0-110 years	BlueTEQ	Live	Not Applicable	Women & Children	PP156	Birmingham Women's and Children's NHS Foundation Trust Manchester University NHS Foundation Trust Sheffield Teaching Hospitals NHS Foundation Trust Sheffield Children's NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
<b>Ataluren</b>	Treatment of Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk	<b>HST22 / AWMSG 3911</b>	2-17 years	BlueTEQ	Live	Live	Women & Children	PP118	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
<b>Avalglucosidase alfa</b>	Treatment of Pompe disease	<b>TA821</b>	0-110 years	BlueTEQ	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Belimumab</b>	Treatment of active autoantibody-positive systemic lupus erythematosus	<b>TA752</b>	0-17 years	BlueTEQ	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Children's NHS Foundation Trust Bristol University Hospitals Birmingham NHS Foundation Trust
<b>Belumosudil</b>	Treatment of chronic graft versus host disease after 2 or more lines of systemic therapy	<b>TA949</b>	12-17 years	BlueTEQ	Live	Live	Women & Children	PP5301	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Great Ormond Street Hospital for Children NHS Foundation Trust Imperial College Healthcare NHS Trust Manchester University NHS Foundation Trust The Newcastle upon Tyne Hospitals NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
<b>Berotrastat</b>	Prevention of recurrent attacks of hereditary angioedema in people 12 years and over	<b>TA738</b>	12-110 years	BlueTEQ	Live	Live	Cancer and Blood	PP236	Currently being confirmed with commissioning teams
<b>Birch bark extract</b>	Treatment of skin wounds associated with dystrophic and junctional epidermolysis bullosa	<b>HST28</b>	6 months-110 years	BlueTEQ	Live	Live	Women & Children	PP5284	Birmingham Women's and Children's NHS Foundation Trust Great Ormond Street Hospital for Children NHS Foundation Trust Guy's and St. Thomas' NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
<b>Burosumab</b>	Treatment of X-linked hypophosphataemia in adults	<b>TA993</b>	18-110 years	BlueTEQ	Live	Live	Women & Children	PP5177	Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
<b>Burosumab</b>	Treatment of X-linked hypophosphataemia in children and young people	<b>HST8</b>	1-17 years	BlueTEQ	Live	Live	Women & Children	PP5177	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Canakinumab</b>	Treatment of periodic fever syndromes: TRAPS, HIDS/MKD and FMF in people aged 2 years and older	<b>Policy</b>	2-110 years	BlueTEQ	Live	Live	Women & Children	PP228	Currently being confirmed with commissioning teams
<b>Cannabidiol</b>	Adjuvant treatment of seizures associated with Dravet syndrome in people aged 2 years and older	<b>TA614</b>	2-17 years	BlueTEQ	Live	Live	Women & Children	PP5203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Cannabidiol</b>	Adjuvant treatment of seizures associated with Lennox-Gastaut syndrome in people aged 2 years and older	<b>TA615</b>	2-17 years	BlueTEQ	Live	Live	Women & Children	PP5203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Cannabidiol</b>	Adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older	<b>TA873</b>	2-17 years	BlueTEQ	Live	Live	Cancer and Blood	PP272	Currently being confirmed with commissioning teams
<b>Cipaglucosidase alfa with Miglustat</b>	Treatment of late-onset Pompe disease in adults	<b>TA912</b>	18-110 years	BlueTEQ	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust

<b>Crovalimab</b>	Treating Paroxysmal nocturnal haemoglobinuria	<b>TA1019</b>	18-110 years	Blueqeq	Live	Live	Cancer and Blood	PPS152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueqeq® forms.
<b>Danicopan as an add-on treatment to a C5 inhibitor</b>	Extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria	<b>TA1010</b>	18-110 years	Blueqeq	Live	Live	Cancer and Blood	PPS152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueqeq® forms.
<b>Danicopan as an add-on treatment to a C5 inhibitor (M4C)</b>	Extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria	<b>TA1010</b>	12-17 years	Blueqeq	Live	In development	Cancer and Blood	M4C	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Leeds Teaching Hospitals NHS Trust Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust
<b>Devrazoxane</b>	Prevention of cardiotoxicity in children aged 16 years and under receiving high-dose anthracyclines or related drugs for the treatment of cancer	<b>Policy</b>	0-16 years	Blueqeq	Live	Not Applicable	Women & Children	PP253	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Great Ormond Street Hospital For Children NHS Foundation Trust Manchester University NHS Foundation Trust Swansea Bay University Health Board Velindre University NHS Trust
<b>Eculizumab</b>	Treatment of paroxysmal nocturnal haemoglobinuria in paediatric patients with a body weight of 5kg or above	<b>AWMSG 0509</b>	0-110 years	Blueqeq	Live	Live	Cancer and Blood	PPS152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueqeq® forms.
<b>Eculizumab</b>	Treatment of atypical haemolytic uraemic (aHUS) syndrome in adults and children	<b>HST1</b>	0-110 years	Blueqeq	Live	Live	Welsh Kidney Network	PPS260	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Swansea Bay University Health Board
<b>Eftasesoctocog alfa</b>	Treatment and prevention of bleeding episodes in haemophilia A in people 2 years and over	<b>TA1051</b>	2-110 years	Blueqeq	Live	(1) In development	In development	PPS327	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Pwys Teaching Health Board Swansea Bay University Health Board
<b>Eltadocagene exparvovec</b>	Treatment of aromatic L-amino acid decarboxylase deficiency	<b>HST26</b>	18 months-110 years	Blueqeq	Live	Not applicable	Women & Children	PP281	Great Ormond Street Hospital For Children NHS Foundation Trust
<b>Eliglustat</b>	Treatment of Type 1 Gaucher disease	<b>HST5</b>	18-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Elosulfase alfa</b>	Treatment of mucopolysaccharidosis type 4A in people of all ages	<b>HST19</b>	0-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Emicizumab</b>	Routine prophylaxis of bleeding episodes in patients with haemophilia A without factor VIII inhibitors who have moderate disease (FVIII = 1% and < 5%) with severe bleeding phenotype.	<b>AWMSG 4742</b>	0-110 years	Blueqeq	Live	Live	Cancer and Blood	In development	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board (Continuation Only) Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
<b>Eplontersen</b>	Treatment of hereditary transthyretin-related amyloidosis	<b>TA1020</b>	18-110 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust
<b>Everolimus</b>	Adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC)	<b>AWMSG 2142</b>	2-17 years	Blueqeq	Live	Live	Cancer and Blood	PP250	Currently being confirmed with commissioning teams
<b>Everolimus</b>	Treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery	<b>AWMSG 1156</b>	18-110 years	Blueqeq	Live	Live	Cancer and Blood	PP274	Currently being confirmed with commissioning teams
<b>Everolimus</b>	Treatment of adult and paediatric patients with subependymal giant cell astrocytoma (SEGA) associated with TSC who require therapeutic intervention but are not amenable to surgery	<b>AWMSG 1156</b>	2-110 years	Blueqeq	Live	In development	Cancer and Blood	PP273	Currently being confirmed with commissioning teams
<b>Evinacumab</b>	Treatment of homozygous familial hypercholesterolaemia in people 12 years and over	<b>TA1002</b>	12-110 years	Blueqeq	Live	Live	Women & Children	PPS308	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Manchester University NHS Foundation Trust
<b>Evinacumab (M4C)</b>	Treatment of homozygous familial hypercholesterolaemia	<b>TA1002</b>	5-11 years	Blueqeq	Live	Live	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Manchester University NHS Foundation Trust
<b>Fenfluramine</b>	Treatment of seizures associated with Dravet syndrome in people aged 2 and older	<b>TAB08</b>	2-17 years	Blueqeq	Live	Live	Women & Children	PPS203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Fenfluramine</b>	Treatment of seizures associated with Lennox-Gastaut syndrome in people aged 2 and older	<b>TA1050</b>	2-17 years	Blueqeq	Live	Live	Women & Children	PPS203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Galsulfase</b>	Treatment of patients with long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis VI (MPS VI; Hurler-Hunter syndrome) or sulfatase deficiency; Maroteaux-Lamy syndrome	<b>AWMSG 0524</b>	0-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Givinostat</b>	Treatment of Duchenne muscular dystrophy in people 6 years and over	<b>TA1157</b>	6-17 years	Blueqeq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
<b>Givosiran</b>	Treatment of acute hepatic porphyria	<b>HST16</b>	12-110 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP252	Cardiff and Vale University Health Board King's College Hospital NHS Foundation Trust
<b>Glycerol Phenylbutyrate</b>	Glycerol Phenylbutyrate for use as an adjunctive therapy for chronic management of patients with urea cycle disorders including deficiencies	<b>AWMSG 1819</b>	0-110 years	Blueqeq	Live	Live	In development	In development	Currently being confirmed with commissioning teams
<b>Home Parenteral Support</b>	Treatment of adults (16 years and over) with type 2 and 3 intestinal failure	<b>Policy</b>	16-110 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	CP210	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Home Parenteral Support</b>	Treatment of children (under 18 years) with type 2 and 3 intestinal failure	<b>Policy</b>	0-17 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust

<b>Imiglucerase</b>	Treatment of Gaucher disease Type 1	<b>Policy</b>	18-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Imifidase</b>	Desensitisation treatment before kidney transplant in people with chronic kidney disease	<b>TA809</b>	18-110 years	Blueqeq	Live	In development	Welsh Kidney Network	PP5256	Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
<b>Imifidase (M4C)</b>	Treatment of desensitisation treatment before kidney transplant in people with chronic kidney disease	<b>TA809</b>	Post-pubescent	Blueqeq	Live	In development	Welsh Kidney Network	M4C	Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust
<b>Infliximab (M4C)</b>	Treatment of severe active Crohn's disease	<b>TA187</b>	6-17 years	Blueqeq	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Children's Hospital
<b>Infliximab (M4C)</b>	Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy	<b>TA329</b>	6-17 years	Blueqeq	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Children's Hospital
<b>Iptacopan</b>	Treatment of paroxysmal nocturnal haemoglobinuria in adults	<b>TA1000</b>	18-110 years	Blueqeq	Live	Live	Cancer and Blood	PP5152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueqeq® forms.
<b>Laronidase</b>	Treatment of mucopolysaccharidosis type I	<b>AWMSG 180</b>	0-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Letermovir (M4C)</b>	Prevention of cytomegalovirus disease after a stem cell transplant ( $>50kg$ )	<b>TA591</b>	0-17 years	Blueqeq	Live	(1) In development	Women & Children	M4C	Currently being confirmed with commissioning teams
<b>Lumasiran</b>	Treatment of primary hyperoxaluria type 1 in people of all ages	<b>HST25</b>	0-110 years	Blueqeq	Live	Live	Women & Children	PP277	Currently being confirmed with commissioning teams
<b>Lutetium (177Lu) oxodotreotide</b>	Treatment of unresectable or metastatic neuroendocrine tumours in adults	<b>TA539</b>	16-110 years	Blueqeq	Live	Not applicable	Cancer and Blood	PP195	Currently being confirmed with commissioning teams
<b>Mercaptopamine bitartrate</b>	Treatment of proven nephropathic cystinosis. Mercaptopamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure	<b>AWMSG 0922</b>	0-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Migalastat</b>	Treatment of Fabry disease	<b>Policy</b>	12-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Miglustat</b>	Treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease	<b>AWMSG 371</b>	0-110 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	CP55	Currently being confirmed with commissioning teams
<b>Mirikizumab (M4C)</b>	Treatment of moderately to severely active ulcerative colitis	<b>TA925</b>	2-17 years	Blueqeq	Live	Live	Women & Children	M4C	Currently being confirmed with commissioning teams
<b>Mirikizumab (M4C)</b>	Treatment of moderately to severely active Crohn's disease	<b>TA1080</b>	2-17 years	Blueqeq	Live	Live	Women & Children	M4C	Currently being confirmed with commissioning teams
<b>Nirsevimab</b>	To reduce the risk of respiratory syncytial virus (RSV) in infants with severe combined immunodeficiency syndrome (SCID)	<b>(WHC/2025/029)</b>	0-2 years	Blueqeq	Live	Not Applicable	Women & Children	As per Green Book	Currently being confirmed with commissioning teams
<b>Nirsevimab</b>	To reduce the risk of respiratory syncytial virus (RSV) in infants with respiratory disease	<b>(WHC/2025/029)</b>	0-1 years	Blueqeq	Live	Not Applicable	Women & Children	As per Green Book	Currently being confirmed with commissioning teams
<b>Nirsevimab</b>	To reduce the risk of respiratory syncytial virus (RSV) in infants with congenital heart disease (CHD)	<b>(WHC/2025/029)</b>	0-1 years	Blueqeq	Live	Not Applicable	Women & Children	As per Green Book	Currently being confirmed with commissioning teams
<b>Nusinersen</b>	Treatment of spinal muscular atrophy	<b>TA1162</b>	0-17 years	Blueqeq	Live	Live	Women & Children	PP191	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Ocrelizumab (M4C)</b>	Treatment of primary progressive multiple sclerosis	<b>TA585</b>	Post-pubescent	Blueqeq	Live	Live	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust
<b>Ocrelizumab (M4C)</b>	Treatment of relapsing-remitting multiple sclerosis	<b>TA333</b>	Post-pubescent	Blueqeq	Live	Live	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust
<b>Odevixibat</b>	Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older	<b>HST17</b>	6 months-17 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP249	Birmingham Women's and Children's NHS Foundation Trust King's College Hospital NHS Foundation Trust Leeds Teaching Hospitals NHS Trust
<b>Patisiran</b>	Treatment of hereditary transthyretin amyloidosis	<b>HST10</b>	16-110 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP187	Royal Free London NHS Foundation Trust
<b>Pegcetacoplan</b>	Treatment of Paroxysmal nocturnal haemoglobinuria	<b>TA778</b>	18-110 years	Blueqeq	Live	In development	Cancer and Blood	PP5152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueqeq® forms.
<b>Pegunigalsidase alfa</b>	Treatment of adults with Fabry disease	<b>TA915</b>	18-110 years	Blueqeq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Pegzilarginase</b>	Treatment of arginase-1 deficiency in people 2 years and over	<b>HST35</b>	2-110 years	Blueqeq	Live	Live	Women & Children	In development	Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board

<b>Pembrolizumab</b>	Treatment of relapsed/refractory classical Hodgkin lymphoma in patients 3-17 years of age who are stem cell transplant-ineligible and have failed brentuximab vedotin	<b>TA967</b>	3-17 years	Blueq	Live	Not Applicable	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Pembrolizumab</b>	Monotherapy for relapsed/refractory classical Hodgkin lymphoma in patients between 3-17 years of age who HAVE previously been treated with stem cell transplantation but never previously received brentuximab vedotin	<b>TA772</b>	3-17 years	Blueq	Live	Not Applicable	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Pembrolizumab</b>	Monotherapy for relapsed/refractory classical Hodgkin lymphoma in patients between 3-17 years of age who have NOT been previously treated with stem cell transplantation or brentuximab vedotin	<b>TA772</b>	3-17 years	Blueq	Live	Not Applicable	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Ravulizumab</b>	Treatment of paroxysmal nocturnal haemoglobinuria	<b>TA698</b>	18-110 years	Blueq	Live	Live	Cancer and Blood	PP5152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueq® forms.
<b>Ravulizumab</b>	Treatment of atypical haemolytic uraemic (aHUS) syndrome in adults and children	<b>TA710</b>	0-110 years	Blueq	Live	Live	Welsh Kidney Network	PP5260	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Swansea Bay University Health Board
<b>Ravulizumab</b>	Treatment of paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH)	<b>AWMSG 4869</b>	0-17 years	Blueq	Live	Live	Women & Children	PP5152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueq® forms.
<b>Risankizumab (M4C)</b>	Treatment of moderately to severely active Crohn's disease	<b>TA888</b>	Post-pubescent	Blueq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board
<b>Risdiplam</b>	Treatment of spinal muscular atrophy in children and adults (NWJCC commissioned in Paeds Only)	<b>TA755</b>	0-15 years	Blueq	Live	Live	Women & Children	PP240	Currently being confirmed with commissioning teams
<b>Ruxolitinib</b>	Treatment of acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over	<b>TA1054</b>	12-110 years	Blueq	Live	Not Applicable	In development	In development	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
<b>Ruxolitinib (M4C)</b>	Treatment of acute graft versus host disease that responds inadequately to corticosteroids	<b>TA1054</b>	2-11 years	Blueq	Live	Not Applicable	In development	In development	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
<b>Sapropterin dihydrochloride</b>	Treatment of hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders	<b>TA729</b>	0-110 years	Blueq	Live	Live	Women & Children	PP223	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Selpercatinib</b>	Treatment of advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over	<b>TA1038</b>	12-16 years	Blueq	Live	Not applicable	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Selumetinib</b>	Treatment of symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over	<b>HST20</b>	3-110 years	Blueq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP267	Guy's and St Thomas' NHS Foundation Trust Manchester University NHS Foundation Trust
<b>Setmelanotide</b>	Treatment obesity and hyperphagia in Bardet-Biedl syndrome (patients aged 6-17 years when treatment starts)	<b>HST31</b>	6-110 years	Blueq	Live	Live	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Somapacitan</b>	Treatment of growth hormone deficiency in people 3 to 17 years	<b>TA1066</b>	3-17 years	Blueq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Somatrogen</b>	Growth disturbance in children and young people aged 3 years and over	<b>TA863</b>	3-17 years	Blueq	Live	In development	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Somatropin</b>	Treatment of growth failure in children	<b>TA188</b>	0-17 years	Blueq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Tafamidis</b>	Treatment of transthyretin amyloidosis with cardiomyopathy in adults	<b>TA984</b>	16-110 years	Blueq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
<b>Teduglutide</b>	Treatment of Short bowel syndrome in people 1 year and above	<b>TA804</b>	1-110 years	Blueq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP265	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Teriflunomide</b>	Treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years	<b>TA303 / 4033</b>	10-17 years	Blueq	Live	Live	Women & Children	NA	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Tofacitinib</b>	Treatment of Juvenile idiopathic arthritis	<b>TA735</b>	2-17 years	Blueq	Live	Live	Women & Children	PP229	Currently being confirmed with commissioning teams
<b>Upadacitinib (M4C)</b>	Treatment of moderately to severely active ulcerative colitis	<b>TA856</b>	12-17 years	Blueq	Live	Live	Women & Children	M4C	Cardiff and Vale University Hospital Alder Hey Children's NHS Foundation Trust
<b>Upadacitinib (M4C)</b>	Treatment of previously treated moderately to severely active Crohn's disease	<b>TA905</b>	12-17 years	Blueq	Live	Live	Women & Children	M4C	Cardiff and Vale University Hospital Alder Hey Children's NHS Foundation Trust
<b>Ustekinumab</b>	Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children	<b>OW25</b>	6-17 years	Blueq	Live	Live	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Vamorolone</b>	Treatment of Duchenne muscular dystrophy in people 4 years and over.	<b>TA1031</b>	4-17 years	Blueq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
<b>Vedolizumab</b>	Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children	<b>OW24</b>	6-17 years	Blueq	Live	Live	Women & Children	In development	Currently being confirmed with commissioning teams

<b>Velaglucerase alfa</b>	Treatment of Type 1 Gaucher disease	<b>Policy</b>	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Volanesorsen</b>	Treatment of Familial chylomicronaemia syndrome in adults	<b>HST13</b>	18-110 years	Blueteq	Live	Live	Women & Children	PP217	Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board
<b>Volanesorsen (M4C)</b>	Treatment of Familial chylomicronaemia syndrome in adults	<b>HST13</b>	16-110 years	Blueteq	Live	Not applicable	Women & Children	M4C	Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board
<b>Voicog alfa</b>	Treatment and prevention of bleeding in adults and children with von Willebrand disease	<b>OW19</b>	0-110 years	Blueteq	Live	Live	Cancer and Blood	PP215	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust
<b>Voretigine neparovec</b>	Treatment of Inherited retinal dystrophies caused by RPE65 gene mutations in adults and children	<b>HST11</b>	16-110 years	Blueteq	Live	In development	Cardiac	PP196	Great Ormond Street Hospital For Children NHS Foundation Trust Greater Manchester Mental Health NHS Foundation Trust
<b>Vutrisiran</b>	Treatment of transthyretin amyloidosis with cardiomyopathy	<b>TA1115</b>	18-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
<b>Vutrisiran</b>	Treatment of hereditary transthyretin-related amyloidosis	<b>TA868</b>	18-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP187	Royal Free London NHS Foundation Trust
<b>Axicabtagene ciloleucel</b>	Treatment diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	<b>TA872</b>	18-110 years	Blueteq	Live (a+b)	Not applicable	Cancer and Blood	CP175	Currently being confirmed with commissioning teams
<b>Axicabtagene ciloleucel</b>	Treatment of relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	<b>TA895</b>	18-110 years	Blueteq	Live (a+b)	Not applicable	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Brexucabtagene autoleucel</b>	Treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	<b>TA893</b>	26-110 years	Blueteq	Live (a+b)	Not applicable	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Brexucabtagene (Formerly KTE-X19)</b>	Treatment of Relapsed or refractory mantle cell lymphoma	<b>TA677</b>	16-110 years	Blueteq	Live (a+b)	Not applicable	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Lisocabtagene maraleucel</b>	Treatment of relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable	<b>TA1048</b>	18-110 years	Blueteq	Live (a+b)	Not Applicable	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Obecabtagene autoleucel</b>	Treatment of elapsed/refractory Philadelphia negative or positive B cell precursor acute lymphoblastic leukaemia in patients aged 26 years and older	<b>TA1116</b>	26-110 years	Blueteq	Live (a+b)	Not Applicable	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Onasemnogene abeparovvec</b>	Treatment of Spinal muscular atrophy type 1	<b>HST15</b>	0-12 months	Blueteq	Live (a+b)	Not applicable	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Onasemnogene abeparovvec</b>	Treatment of presymptomatic spinal muscular atrophy	<b>HST24</b>	0-12 months	Blueteq	Live (a+b)	Not applicable	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Tisagenlecleucel-T</b>	Treatment of Relapsed or refractory B-cell acute lymphoblastic leukaemia in people up to 25 years	<b>TA554</b>	0-25 years	Blueteq	Live (a+b)	Not applicable	Cancer and Blood	PP185	Currently being confirmed with commissioning teams
<b>Atidarsagene autotemcel</b>	Treatment of metachromatic leukodystrophy in children	<b>HST18</b>	0-17 years	Blueteq	Live (a+b+c)	Not applicable	Women & Children	PP257	Greater Manchester Mental Health NHS Foundation Trust
<b>Etranacogene dezaparovvec</b>	Treatment of moderately severe or severe haemophilia B	<b>TA989</b>	18-110 years	Blueteq	Live (a+b+c)	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Exagamglogene autotemcel</b>	Treatment of transfusion-dependent beta-thalassaemia in people 12 years and over	<b>TA1003</b>	12-110 years	Blueteq	Live (a+b+c)	Not Applicable	Cancer and Blood	In development	Imperial College Healthcare NHS Trust Manchester University NHS Foundation Trust University College London Hospitals NHS Foundation Trust
<b>Exagamglogene autotemcel</b>	Treatment of severe sickle cell disease in people 12 years and over	<b>TA1044</b>	12-110 years	Blueteq	Live (a+b+c)	Not Applicable	Cancer and Blood	In development	Imperial College Healthcare NHS Trust Manchester University NHS Foundation Trust University College London Hospitals NHS Foundation Trust
<b>Belzutifan (M4C)</b>	Treatment of tumours associated with von Hippel-Lindau disease	<b>TA1011</b>	Post-pubescent	Prior Approval	Not Applicable	Not Applicable	Cancer and Blood	M4C	Currently being confirmed with commissioning teams
<b>Natizumab (M4C)</b>	Treatment of highly active relapsing-remitting multiple sclerosis after disease-modifying therapy	<b>TA1126</b>	In development	TBC	Not Applicable	Not Applicable	In development	M4C	Currently being confirmed with commissioning teams
<b>Vanzacaftor-tezacaftor-deutivacaftor</b>	Treatment of cystic fibrosis with an F508del mutation in the CFTR gene in people 6 years and over	<b>TA1085</b>	6-110 years	N/A	Not Applicable	Not Applicable	Cardiac and Thoracic	PP198	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool Heart and Chest Hospital NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust University Hospitals of North Midlands NHS Trust
<b>Venetoclax with obinutuzumab (M4C)</b>	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia	<b>TA1119</b>	Post-pubescent	Prior Approval	Not Applicable	Not Applicable	In development	M4C	Currently being confirmed with commissioning teams
<b>Agalsidase alfa (M4C)</b>	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	<b>M4C Policy</b>	7-18 years	TBC	(1) In development	(1) In development	Women & Children	M4C	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust
<b>Agalsidase beta (M4C)</b>	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	<b>Policy</b>	8-18 years	TBC	(1) In development	(1) In development	Women & Children	M4C	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust

<b>Ambrisentan</b>	Treatment of pulmonary arterial hypertension (PAH)	<b>AWMSG 4819</b>	8-110 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Bevacizumab</b>	Treatment of vestibular schwannoma in neurofibromatosis type 2	<b>Policy</b>	0-110 years	TBC	(1) In development	(1) In development	Neurosciences, Complex Conditions & Rare Diseases	CP254	Cambridge University Hospitals NHS Foundation Trust Manchester University Hospitals NHS Foundation Trust Guy's & St Thomas' NHS Foundation Trust Oxford University Hospitals NHS Trust
<b>Blinatumomab</b>	Treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation	<b>AWMSG 0519</b>	1-17 years	Blueq	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Blinatumomab (M4C)</b>	For the treatment of relapsed/refractory negative B-precursor acute lymphoblastic leukaemia in individuals up to 17 years of age	<b>TA450/AWMSG 3769</b>	0-17 years	Blueq	(1) In development	(1) In development	In development	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Blinatumomab (M4C)</b>	Treatment of patients in first complete haematological complete remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in CHLD patients.	<b>TA589</b>	1-17 years	Blueq	(1) In development	(1) In development	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Brentuximab (M4C)</b>	Brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option in CHLD patients <b>Likely 12-17 years</b>	<b>TA524</b>	12-17 years	Blueq	(1) In development	(1) In development	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Brivaracetam</b>	Treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy	<b>AWMSG 4614</b>	2-17 years	Blueq	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>C1 esterase inhibitor</b>	Prophylactic treatment of hereditary angioedema (HAE)	<b>Policy</b>	In development	Blueq	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Certolizumab pegol (M4C)</b>	Treatment of active psoriatic arthritis after inadequate response to DMARDs	<b>TA445</b>	Post-pubescent	Prior Approval	(1) In development	(1) In development	Women & Children	M4C	Currently being confirmed with commissioning teams
<b>Dabrafenib + trametinib</b>	Treatment of BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	<b>TA977</b>	1-17 years	Blueq	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Dasatinib</b>	Treatment of paediatric patients weighing ≥ 10 kg with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (Ph+ChI-CP) or Ph+ChI-CP resistant or intolerant to prior therapy including imatinib	<b>AWMSG 0319</b>	0-17 years	Blueq	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Defibrotide</b>	Treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.	<b>AWMSG 0515</b>	In development	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Dinutuximab beta</b>	Treatment of neuroblastoma	<b>TA538</b>	1-17 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Emicizumab</b>	Prophylaxis in people with congenital haemophilia A without Factor VIII inhibitors (all ages)	<b>Policy</b>	0-110 years	Blueq	(1) In development	(1) In development	Cancer and Blood	PP189	Currently being confirmed with commissioning teams
<b>Emicizumab</b>	Prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages)	<b>Policy</b>	0-110 years	Blueq	(1) In development	(1) In development	Cancer and Blood	PPS167	Currently being confirmed with commissioning teams
<b>Eplontersen (M4C)</b>	Treatment of hereditary transthyretin-related amyloidosis	<b>TA1020</b>	Post-pubescent	TBC	(1) In development	(1) In development	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust
<b>Garadacimab</b>	Prevention of recurrent attacks of hereditary angioedema in people 12 years and over	<b>TA1101</b>	12-110 years	Blueq	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Glofitamab with gemtuzumab and oxaliplatin (M4C)</b>	Glofitamab with gemtuzumab and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma	<b>TA1113</b>	In development	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Golimumab (M4C)</b>	Treatment of psoriatic arthritis	<b>TA220</b>	Post-pubescent	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Guselkumab</b>	Treatment of moderately to severely active ulcerative colitis	<b>TA1094</b>	Post-pubescent	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Guselkumab</b>	Treatment of previously treated moderately to severely active Crohn's disease	<b>TA1095</b>	Post-pubescent	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Holoclar</b>	Treatment of limbal stem cell deficiency after eye burns	<b>TA467</b>	In development	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Icatibant acetate</b>	Treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency	<b>AWMSG 3293</b>	2-110 years	TBC	(1) In development	(1) In development	Cardiac and Thoracic	In development	Currently being confirmed with commissioning teams
<b>Ipilimumab</b>	Treatment of advanced (unresectable or metastatic) melanoma in adolescents	<b>AWMSG 1818</b>	12-17 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Iptacopan (M4C)</b>	Treatment of paroxysmal nocturnal haemoglobinuria in adults	<b>TA1000</b>	Post-pubescent	TBC	(1) In development	(1) In development	Cancer and Blood	M4C	Please note that Haematologists in local Health Boards may prescribe this drug for PHH under the advice of the PHH National Service. This will include having access to complete the appropriate Blueq® forms.
<b>Lanadelumab</b>	Prevention of recurrent attacks of hereditary angioedema	<b>TA606</b>	12-110 years	TBC	(1) In development	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams

<b>Lanadelumab (M4C)</b>	Prevention of recurrent attacks of hereditary angioedema	<b>TA606</b>	12-110 years	TBC	(1) In development	(1) In development	Cancer and Blood	M4C	Currently being confirmed with commissioning teams
<b>Larotrectinib</b>	Treatment NTRK fusion-positive solid tumours	<b>TA630</b>	0-17 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Leniolisib</b>	Treatment of activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	<b>HST33</b>	12-110 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Lisocabtagene maraleucel</b>	Treatment of relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment	<b>TA1159</b>	18-110 years	Blueq	(1) In development	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Marstacimab</b>	Severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over	<b>TA1073</b>	12-110 years	Blueq	(1) In development	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Mifamurtide</b>	Treatment of osteosarcoma	<b>TA235</b>	2-17 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Nitisinone</b>	Treatment of adult patients with alkaptonuria	<b>AWMSG 2322</b>	18-110 years	TBC	(1) In development	(1) In development	Neurosciences, Complex Conditions & Rare Diseases	In development	Currently being confirmed with commissioning teams
<b>Nivolumab-relatlimab</b>	For untreated unresectable or metastatic melanoma	<b>TA950</b>	12-17 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Risankizumab (M4C)</b>	Treatment of moderately to severely active ulcerative colitis	<b>TA1108</b>	Post-pubescent	TBC	(1) In development	(1) In development	Women & Children	M4C	Cardiff and Vale University Health Board
<b>Rituximab / Eculizumab</b>	Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in people with haemoglobinopathies	<b>Policy</b>	0-110 years	TBC	(1) In development	(1) In development	In development	PPS237	Currently being confirmed with commissioning teams
<b>Romiplostim (M4C)</b>	Treatment of chronic immune thrombocytopenia	<b>TA211</b>	1-17 years	TBC	(1) In development	(1) In development	In development	M4C	Currently being confirmed with commissioning teams
<b>Ruxolitinib</b>	Treatment of chronic graft versus host disease that responds inadequately to corticosteroids in people 12 years and over	<b>TA840</b>	12-17 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Ruxolitinib (M4C)</b>	Treatment of chronic graft versus host disease that responds inadequately to corticosteroids	<b>TA840</b>	2-11 years	Blueq	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Sebelipase alfa</b>	Treatment of Wolman Disease	<b>HST30</b>	0-2 years	TBC	(1) In development	(1) In development	In development	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Secukinumab (M4C)</b>	Treatment of active psoriatic arthritis after inadequate response to DMARDs	<b>TA445</b>	6-17 years	TBC	(1) In development	(1) In development	Women & Children	M4C	Currently being confirmed with commissioning teams
<b>Sellecipag</b>	Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies	<b>AWMSG 700</b>	18-110 years	TBC	(1) In development	(1) In development	Cardiac	PP105	Currently being confirmed with commissioning teams
<b>Selpercatinib</b>	Treatment of advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over	<b>TA1039</b>	12-16 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
<b>Talimogene laherparepvec</b>	Treatment of unresectable metastatic melanoma	<b>TA410</b>	0-110 years	TBC	(1) In development	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams
<b>Talquetamab (M4C)</b>	Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments	<b>TA1114</b>	Post-pubescent	Prior Approval	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Velmanase alfa</b>	Treatment of alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment	<b>HST29</b>	0-17 years	TBC	(1) In development	(1) In development	In development	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
<b>Vorasidenib</b>	Treatment of astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over	<b>TA1147</b>	12-17 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
<b>Cerliponase alfa</b>	Treatment of neuronal ceroid lipofuscinosis type 2 in children	<b>HST34</b>	0-17 years	Blueq	Disabled	Live	Women & Children	PP262	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Tofacitinib (M4C)</b>	Treatment of moderately to severely active ulcerative colitis in children	<b>TA547</b>	2-17 years	Blueq	Live	Live	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board
<b>Ivacaftor-tezacaftor-elixacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor</b>	Treatment of cystic fibrosis	<b>TA988</b>	2-110 years	N/A	Not applicable	Not applicable	Cardiac and Thoracic	PP198	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool Heart and Chest Hospital NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust University Hospitals of North Midlands NHS Trust